Structure and inhibition mechanism of the human citrate transporter NaCT

David B. Sauer, Jinmei Song, Bing Wang, Jacob K. Hilton, Nathan K. Karpowich, Joseph A. Mindell (), William J. Rice () and Da-Neng Wang ()
Additional contact information
David B. Sauer: New York University School of Medicine
Jinmei Song: New York University School of Medicine
Bing Wang: New York University School of Medicine
Jacob K. Hilton: National Institute of Neurological Disorders and Stroke, National Institutes of Health
Nathan K. Karpowich: New York University School of Medicine
Joseph A. Mindell: National Institute of Neurological Disorders and Stroke, National Institutes of Health
William J. Rice: New York University School of Medicine
Da-Neng Wang: New York University School of Medicine

Nature, 2021, vol. 591, issue 7848, 157-161

Abstract: Abstract Citrate is best known as an intermediate in the tricarboxylic acid cycle of the cell. In addition to this essential role in energy metabolism, the tricarboxylate anion also acts as both a precursor and a regulator of fatty acid synthesis1–3. Thus, the rate of fatty acid synthesis correlates directly with the cytosolic concentration of citrate4,5. Liver cells import citrate through the sodium-dependent citrate transporter NaCT (encoded by SLC13A5) and, as a consequence, this protein is a potential target for anti-obesity drugs. Here, to understand the structural basis of its inhibition mechanism, we determined cryo-electron microscopy structures of human NaCT in complexes with citrate or a small-molecule inhibitor. These structures reveal how the inhibitor—which binds to the same site as citrate—arrests the transport cycle of NaCT. The NaCT–inhibitor structure also explains why the compound selectively inhibits NaCT over two homologous human dicarboxylate transporters, and suggests ways to further improve the affinity and selectivity. Finally, the NaCT structures provide a framework for understanding how various mutations abolish the transport activity of NaCT in the brain and thereby cause epilepsy associated with mutations in SLC13A5 in newborns (which is known as SLC13A5-epilepsy)6–8.

Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://www.nature.com/articles/s41586-021-03230-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:591:y:2021:i:7848:d:10.1038_s41586-021-03230-x

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-021-03230-x

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().